Dr. Michael D. Jain, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 78
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
FL license ME132251
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- H Lee Moffitt Cancer Ctr and Res Inst Life Time Cancer Scrn Ctr Inc (1,178 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 78
- Services billed
- 242
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 99 | 55 |
| Established patient office or other outpatient visit, 40-54 minutes | 65 | 40 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Tampa, FL | 128 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Tampa, FL | 44 |
| Eliquis (apixaban) Other prescribers in Tampa, FL | 16 |
| Ondansetron Hcl Other prescribers in Tampa, FL | 15 |
| Oxycodone Hcl Other prescribers in Tampa, FL | 14 |
| Tamsulosin Hcl Other prescribers in Tampa, FL | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 14 payments worth $17,627 in total to this clinician.
| Kite Pharma, Inc. | $13,890 |
|---|---|
| Janssen Scientific Affairs, LLC | $3,525 |
| Celgene Corporation | $131 |
| Novartis Pharmaceuticals Corporation | $81.39 |
| Consulting Fee | $15,525 |
|---|---|
| Travel and Lodging | $1,382 |
| Food and Beverage | $720 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Kite Pharma, Inc. May 4, 2025 | Consulting Fee Yescarta · CELLT Company’s description;4099358;GTF;12983510 | $12,000 |
| Janssen Scientific Affairs, LLC Jul 16, 2025 | Consulting Fee | $3,525 |
| Kite Pharma, Inc. May 2, 2025 | Travel and Lodging Yescarta · CELLT · travel to Tyson Corner, VA · in-kind Company’s description;4099653;GTF;12983510 | $955 |
| Kite Pharma, Inc. May 2, 2025 | Travel and Lodging Yescarta · CELLT · travel to Tyson Corner, VA · in-kind Company’s description;4099070;GTF;12983510 | $427 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $150,181 in research payments for these studies, mostly to the institutions running them.
- Long Term Follow Up of Patients Exposed to Lentiviral Based CD19 Directed CAR T Cell Therapy
Novartis Pharmaceuticals Corporation - A Phase 2, Single-Arm, Open-Label Study using Itacitinib as Pre-Modulation in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CAR-T-Cell Therapy
Incyte Corporation - A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma.
Genmab U.S., Inc. - Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL
Novartis Pharmaceuticals Corporation - A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT07015242
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.